Facebook Linkedin RSS Twitter Youtube
Home 2024

Novartis

Gee WIZ: Novartis’ “Glue Degrader” Drug Candidate for Sickle Cell Shows Promise in Animal Studies
GEN Edge

Gee WIZ: Novartis’ “Glue Degrader” Drug Candidate for Sickle Cell Shows Promise in Animal Studies

Bertozzi’s TwoStep Therapeutics to Target Solid Tumors With Engineered Peptide Drug Delivery Vehicle
Cancer

Bertozzi’s TwoStep Therapeutics to Target Solid Tumors With Engineered Peptide Drug Delivery Vehicle

JAK Attack: Ajax Takes Aim at Myelofibrosis
Cancer

JAK Attack: Ajax Takes Aim at Myelofibrosis

Novartis to Acquire Mariana for Up to $1.75B, Expanding Radiopharma Pipeline
Drug Discovery

Novartis to Acquire Mariana for Up to $1.75B, Expanding Radiopharma Pipeline

Top 10 Best-Selling Cell and Gene Therapies
A-Lists

Top 10 Best-Selling Cell and Gene Therapies

Skin in the Game: Oruka Takes on Blockbuster Drugs for Psoriasis, Dermatological Disorders
Drug Discovery

Skin in the Game: Oruka Takes on Blockbuster Drugs for Psoriasis, Dermatological Disorders

Vertex to Acquire Alpine Immune Sciences for $4.9B, Broadening Kidney Drug Pipeline
Drug Discovery

Vertex to Acquire Alpine Immune Sciences for $4.9B, Broadening Kidney Drug Pipeline

Perfusion Models Improve Pre-Stage Bioprocessing Efficiency
Bioprocessing

Perfusion Models Improve Pre-Stage Bioprocessing Efficiency

Cloaking Device: Liu, Joung Launch $100M Nvelop Therapeutics to Advance Delivery of Genetic Cargo
Drug Discovery

Cloaking Device: Liu, Joung Launch $100M Nvelop Therapeutics to Advance Delivery of Genetic Cargo

Novartis to Acquire MorphoSys for $2.9B, Bolstering Oncology Pipeline
Cancer

Novartis to Acquire MorphoSys for $2.9B, Bolstering Oncology Pipeline

123...55Page 1 of 55
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.